ReviewWorld journal of microbiology & biotechnology2025
The antibacterial activity, action mechanisms and prospects of Baicalein as an antibacterial adjuvant.
Review in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Antimicrobial Strategies in the Era of Resistance: It Is Too Early to Give Up Antibiotic Therapy.International journal of molecular sciences · 2026Review
- Harnessing the Antimicrobial Potential of Baicalein-Coated FeACS applied materials & interfaces · 2026Article
- Study on the Mechanism of Action of Baicalein in Inhibiting the Invasion ofAntioxidants (Basel, Switzerland) · 2026Article
- Baicalin potentiates cefquinome against animal-origin ESBL-Frontiers in veterinary science · 2026Article
- Kaempferol inhibitsFrontiers in microbiology · 2026Article
- The WHO priority list of antibiotic-resistant bacteria: challenges and opportunities for next-generation antimicrobial development.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given the rising issue of antimicrobial resistance and the slow progress in the development of novel antibiotics, the identification of antimicrobial agents from ethnopharmacological plants has become a promising strategy. Baicalein is a flavonoid compound derived from medicinal plants with a wide range of pharmacological activities. It exhibits broad-spectrum antimicrobial activity against various clinically relevant bacteria and fungi in a dose-dependent manner. Moreover, baicalein suppresses the development of antimicrobial resistance, enhances the efficacy of conventional antibiotics, and converts their bacteriostatic effects into bactericidal activity. This highlights its potential as both an antimicrobial agent and an antibiotic adjuvant. This review systematically summarizes the antimicrobial properties of baicalein, both as a monotherapy and in combination therapy, focusing on its effects on planktonic and biofilm cells, as well as its beneficial actions in vivo infections. Moreover, we provide an in-depth analysis of the potential molecular targets of baicalein, including the cell membrane and cell wall, core metabolic processes, resistance mechanisms, and quorum sensing systems. We also discuss the limitations of current research and outline future research directions, emphasizing the need for high-quality studies to comprehensively evaluate the clinical efficacy and safety of baicalein in infection treatment. This review aims to offer new insights and recommendations for its future clinical translation.
Indexed as
Identifiers
40781174What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.